GB0101227D0 - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- GB0101227D0 GB0101227D0 GBGB0101227.7A GB0101227A GB0101227D0 GB 0101227 D0 GB0101227 D0 GB 0101227D0 GB 0101227 A GB0101227 A GB 0101227A GB 0101227 D0 GB0101227 D0 GB 0101227D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical compounds
- pharmaceutical
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0101227A GB2372986A (en) | 2001-01-17 | 2001-01-17 | 2-oxo, 4-hydroxy pyrroles and quinolines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0101227A GB2372986A (en) | 2001-01-17 | 2001-01-17 | 2-oxo, 4-hydroxy pyrroles and quinolines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0101227D0 true GB0101227D0 (en) | 2001-02-28 |
| GB2372986A GB2372986A (en) | 2002-09-11 |
Family
ID=9906997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0101227A Withdrawn GB2372986A (en) | 2001-01-17 | 2001-01-17 | 2-oxo, 4-hydroxy pyrroles and quinolines |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2372986A (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| WO2005009971A1 (en) * | 2003-07-24 | 2005-02-03 | Astellas Pharma Inc. | Quinolone derivative or salt thereof |
| US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
| US7141592B2 (en) * | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| PL1773816T3 (en) | 2004-06-24 | 2015-06-30 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| HUE049976T2 (en) | 2005-12-28 | 2020-11-30 | Vertex Pharma | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| AU2007271734B2 (en) | 2006-07-05 | 2012-03-29 | Certa Therapeutics Pty. Ltd. | Therapeutic compounds |
| MX2009000944A (en) * | 2006-07-26 | 2009-02-04 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase. |
| KR101852173B1 (en) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US9062076B2 (en) * | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| BR112014021090B1 (en) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | PHARMACEUTICAL COMPOSITION AND USE OF N-[2,4-BIS(1,1-DIMETHYLethyl)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE3-CARBOXAMIDE IN THE PREPARATION OF THE SAME |
| DE102014108210A1 (en) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | rodenticide |
| KR20170063954A (en) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| AU2018208458B2 (en) * | 2017-01-10 | 2020-07-16 | ETH Zürich | Cell-protective compounds and their use |
| CN110546133A (en) | 2017-02-03 | 2019-12-06 | 塞尔塔治疗有限公司 | Anti-fibrotic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9302419A (en) * | 1992-04-28 | 1994-03-31 | American Home Prod | DERIVATIVES OF TETRONIC ACID, TIOTETRONIC AND TETRAMIC. |
| US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
-
2001
- 2001-01-17 GB GB0101227A patent/GB2372986A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB2372986A (en) | 2002-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1450824A4 (en) | Pharmaceutical composition | |
| GB0104534D0 (en) | Pharmaceutical combination | |
| PL366510A1 (en) | Pharmaceutical combinations | |
| GB0101225D0 (en) | Pharmaceutical compounds | |
| GB0101227D0 (en) | Pharmaceutical compounds | |
| EP1408896A4 (en) | Pharmaceutical composition | |
| GB0031084D0 (en) | Pharmaceutical compounds | |
| GB0124523D0 (en) | Pharmaceutical combination | |
| GB0116107D0 (en) | Pharmaceutical composition | |
| GB0129270D0 (en) | Pharmaceutical combination | |
| GB0019272D0 (en) | Pharmaceutical compounds | |
| GB0129397D0 (en) | Pharmaceutical combination | |
| GB0129872D0 (en) | Novel pharmaceutical | |
| GB0024318D0 (en) | Pharmaceutical compounds | |
| GB0129395D0 (en) | Pharmaceutical combination | |
| AU2002342940A8 (en) | New pharmaceutical compounds | |
| GB0005366D0 (en) | Pharmaceutical compounds | |
| GB0130510D0 (en) | Novel pharmaceutical | |
| GB0130509D0 (en) | Novel pharmaceutical | |
| GB0129876D0 (en) | Novel pharmaceutical | |
| GB0130511D0 (en) | Novel pharmaceutical | |
| GB0128138D0 (en) | Pharmaceutical use | |
| GB0123669D0 (en) | Pharmaceutical compounds | |
| GB0122199D0 (en) | Pharmaceutical compounds | |
| GB0127023D0 (en) | Pharmaceutical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |